Our Technology
Next generation synthetic vector based therapeutics the ONCoat™ vector engineering platform
ONCoat™
DevaCell is developing next-generation, engineered, synthetic vector based therapeutics based on the company’s ONCoat™ synthetic vector platform technology, enabling a pipeline of high impact therapeutics across three key segments: armed oncolytic immunotherapeutics, vaccines, and gene therapy/gene editing applications.
ONCoat™ Synthetic Vector Process
Highly infectious
Highly immunogenic
High transduction efficiency
Acts as a foundation for sol-gel reaction
Synergistic role in endosomal lysis and escape
Masks the surface of the virus
Transitions through pH mediated degradation in late endosomal stage
Forms a foundation for high density, flexible functionalization
High density surface functionalization
Bi-functional PEG molecules
One side strongly attaches to ONCoat™ surface through specific linker chemistry
Solution facing side carries folate molecules enabling efficient cellular uptake
ONCoat™ Virus – Uptake Mechanism
KEY ADVANTAGES
Prevents Viral Neutralization:
Potential for enhanced immune system activation by preventing viral vector neutralization and increasing gene expression
Enables Repeat and Systemic Delivery:
Synthetic vector platform enables repeat administration and systemic delivery, without neutralizing antibody effects
Safety:
Improved safety with potential to reduce dose levels and toxicity
Scalable:
Low cost, scalable manufacturing process Strong intellectual property position with multiple worldwide patent applications covering the ONCoat™ platform technology, next generation therapeutics, vaccines, and gene therapy/gene editing applications, as well as methods, process and manufacturing IP
Designer Encapsulated Vector Assembly
Get In Touch
6650 Lusk Blvd.
Suite B105
San Diego CA 92121
info@devacell.com